Background: Modern advances in genetic sequencing techniques have allowed for increased availability of genetic testing for hereditary cancer syndromes. Consequently, more people are being identified as mutation carriers and becoming aware of their increased risk of malignancy. Testing is commonplace for many inheritable cancer syndromes, and with that comes the knowledge of being a gene carrier for some patients. With increased risk of malignancy, many guidelines recommend that gene carriers partake in risk reduction strategies, including risk-reducing surgery for some syndromes. This review explores the quality-of-life consequences of genetic testing and risk-reducing surgery.
Introduction
Next-generation sequencing techniques allow for analysis of many different genes simultaneously, resulting in increased speed and access, and lower costs of testing for hereditary cancer syndromes. As a result, an increasing number of patients are seeking genetic counselling and undergoing germline mutational testing. Patients with hereditary cancer syndromes may choose several strategies for cancer risk reduction, including surveillance, risk-reducing surgery (RRS), chemoprevention and, perhaps, lifestyle modifications.
Genetic counselling and testing can adversely affect a patient or family's emotional and mental well-being. In a systematic review, Eijzenga and colleagues 1 identified several areas of concern for patients, including: coping with potential cancer risk; practical concerns, such as access to health and/or life insurance, and anxiety during the wait for genetic testing results; family-related conflicts, such as changes in family communication and/or dynamics, and feelings of guilt or responsibility towards family members; children-related issues, such as guilt towards their children and uncertainty regarding how or when to inform their children, although worries about a child's future risk acted as a strong motivator for patients to pursue genetic counselling; anxieties regarding living with an increased cancer risk; and overwhelming emotions such as stress, fear, anger, frustration, anxiety, and feelings of loss. However, genetic testing can be associated with positive emotions, such as relief and reduced anxiety, once the results have been revealed 1 . When discussing recommendations for genetic counselling to patients with potential hereditary cancer syndromes, physicians should be aware of these concerns and address them as the situation demands.
Risk-reducing surgery
For many hereditary cancer syndromes, RRS is the single most effective strategy for preventing cancer. In appropriate situations, RRS can improve life expectancy and provide important health-related quality-of-life (HRQOL) benefits, including avoidance of adjuvant therapy, reduced surveillance and reduction in cancer anxiety. However, RRS is irreversible and can often have substantial negative impacts on HRQOL. The spectrum of adverse outcomes after RRS is broad and includes psychosocial well-being, anxiety, depression, body image, sexual well-being, pain and gastrointestinal function. RRS can also impact social, academic and financial outcomes for some patients.
Patients who are contemplating RRS for hereditary cancer syndromes (and their physicians) must consider several important factors: (1) 10 ; however, bilateral nephrectomy is an impractical strategy.
Subsequent sections review the indications, surgical approaches and outcomes of RRS for three common hereditary cancer syndromes, with an emphasis on shortand long-term HRQOL outcomes.
Hereditary breast and ovarian cancer
Mutations in the BRCA1/2 genes account for 3-5 per cent of breast cancer and 10 per cent of ovarian cancer 11 . For BRCA1, the average cumulative risk of breast cancer in women by age 80 years is 67 per cent, and that of ovarian cancer is 45 per cent 12 . In women with BRCA2 mutations, these respective proportions are 66 and 12 per cent 12 .
Breast cancer management strategies
Many national and international consensus guidelines have published recommendations for screening and risk reduction of hereditary breast and ovarian cancer 11, 13, 14 .
Quality-of-life implications of risk-reducing cancer surgery e123
The National Comprehensive Cancer Network (NCCN) guidelines 13 recommend that BRCA1 and BRCA2 mutation carriers undergo increased breast cancer screening, consider risk-reducing bilateral mastectomy (RRM) and undergo bilateral RRSO once child bearing is completed. Increased breast cancer screening in genetic mutation carriers is estimated to reach a sensitivity greater than 90 per cent in identifying early-stage breast cancers 15 -17 . On the other hand, RRM is a very efficacious procedure and can reduce the risk of breast cancer by 89⋅5-100 per cent 18, 19 , but does not necessarily improve overall survival 20, 21 . For BRCA1/2 carriers without a previous breast cancer diagnosis, RRSO is associated with an estimated 45 per cent reduction in breast cancer risk and a 65 per cent reduction in all-cause mortality 22 . Alternatively, endocrine prophylaxis with tamoxifen is associated with breast cancer risk reduction in patients with BRCA2 mutations 12, 23 .
Patients and surgeons can choose from multiple different techniques for RRM and reconstruction options. Mastectomy options include a total bilateral mastectomy without reconstruction, a skin-sparing mastectomy with reconstruction, and a nipple-sparing mastectomy with reconstruction. Reconstruction options include autologous-based reconstruction or alloplastic reconstruction with expanders and implants. The majority of women who undergo RRM elect for immediate breast reconstruction with implants 12 . Although the surgical technique is variable, the risk of breast cancer is not significantly different amongst techniques.
Although RRM substantially reduces breast cancer risk for patients with BRCA1/2 mutations, it is a major and irreversible surgical intervention. Surgical complications include bleeding/haematoma, skin necrosis, infection, capsular contracture and seroma 24 -26 . A Cochrane review 27 of RRM found a rate of adverse events requiring reoperation of 4 per cent in patients without reconstruction and up to 49 per cent in those with reconstruction, based on a review of case series. In a prospective study 26 of 112 women undergoing RRM and immediate construction, 21 per cent of all patients had at least one complication. Specifically, 10 per cent had bleeding, 9 per cent had infection and 14 per cent had capsular contracture; 33 per cent of women required reoperation 26 .
Quality of life after risk-reducing mastectomy
Several studies have reported HRQOL outcomes among patients following RRM. In a systematic review of 22 studies, Razdan and co-workers 28 evaluated the psychosocial well-being and HRQOL of patients undergoing RRM. They noted that 61-100 per cent reported satisfaction with the RRM. Among studies that reported objective measures of psychosocial well-being, 72 per cent of women reported favourable results. The authors concluded that women were highly satisfied with both their decision and surgical outcomes. Additionally, patient satisfaction does not appear to diminish with time. One study 29 with a mean follow-up time of 14⋅5 years reported that most women were satisfied with their decision and outcomes.
Furthermore, RRM appears to decrease cancer-related anxiety 30 -32 . A prospective study 32 evaluated women with high-risk cancer who underwent RRS (RRM, RRM plus RRSO, or RRSO alone) in comparison with age-and risk-matched control patients in the same high-risk group who did not have surgery. They found that women who underwent RRS reported greater reductions in perceived cancer risk and cancer-associated anxiety. Reduction in anxiety and cancer-related distress among BRCA1/2 carriers was notable when compared to both carriers who opted for surveillance and non-carrier individuals 31 . McCarthy et al. 30 and Pusic and co-workers 33 published results from the Mastectomy Reconstruction Outcomes Consortium and reported that women who underwent RRM with immediate reconstruction had significantly decreased anxiety 1 and 2 years after surgery compared with baseline scores.
Despite the potential benefits, RRM may also affect HRQOL negatively for certain patients 28,34 -37 . Undesirable outcomes may include a negative impact on body image 34, 35 , decreased sexual sensation 34, 37 , decreased sexual enjoyment 34, 36 and increased breast pain 34, 35 . In their systematic review, Razdan and co-workers 28 identified seven studies that evaluated body image; 66 per cent of the patients had a favourable body image after surgery, but one study 35 showed that most patients had significantly decreased views of their body image throughout the follow-up to 21 months. Furthermore, a subset of patients noted that their breasts felt unpleasant and were either not satisfied with their appearance or embarrassed by their naked body 35 .
Ovarian cancer management strategies
In patients with BRCA1/2 mutations, risk reduction strategies for ovarian cancer include screening with transvaginal ultrasonography, carbohydrate antigen 125 blood testing, chemoprevention through oral contraception and RRSO 11, 13, 14 . Owing to the limitations of early detection and poor prognosis of advanced cancer, NCCN guidelines 13 recommend RRSO after completion of childbearing by age 35-40 years to reduce the risk of ovarian or fallopian tube cancer. RRSO is generally an outpatient, minimally invasive surgical procedure with few short-term side-effects. For patients with BRCA1/2 mutations, the risk of ovarian and fallopian tube cancer is reduced by approximately 80 per cent after RRSO 38 . Furthermore, RRSO may reduce the all-cause mortality rate by up to 77 per cent for women with BRCA1/2 mutations 22, 39 .
Quality of life after risk-reducing salpingo-oophorectomy
Despite the oncological benefits of RRSO, the procedure induces surgical menopause and can negatively affect HRQOL. In a case-control study, Michelsen and colleagues 40 reported that women who underwent RRSO had more palpitations, constipation, pain, stiffness, osteoporosis and musculoskeletal disease than matched controls. However, patients who underwent RRSO had lower levels of mental distress and depression 40 .
Sexual health can be affected substantially by RRSO. A recent cross-sectional study 41 of women who had RRSO found the prevalence of female sexual dysfunction to be 74 per cent and that of hypoactive sexual desire to be 73 per cent. Fang and co-workers 42 published the results of a prospective study comparing mutation carriers who elected to undergo screening versus RRSO. Women who had RRSO had poorer quality of life, greater discomfort and less satisfaction with sexual activity at 1-month follow-up; by 6 months, however, most of these deficits had improved. A similar study reported by Chapman et al. 43 surveyed women after surgery and found a decrease in sexual function after RRSO. However, the use of hormone replacement therapy may mitigate sexual dysfunction after RRSO 6 .
Summary
When viewed collectively, the HRQOL implications of patients undergoing genetic testing for hereditary breast and ovarian cancer, and subsequent RRS, appear to be relatively positive. After RRM, most patients report satisfaction with their decision and outcomes with no significant negative impact on HRQOL. However, some patients experience negative aesthetic changes, changes in body perception, pain and sexual dysfunction after RRM. Nonetheless, most patients are satisfied with their decision and do not regret their choice 28 . For ovarian cancer, RRSO markedly reduces the risk of cancer of the ovary and fallopian tube. The timing of RRSO depends upon childbearing choices and HRQOL concerns after surgery.
Familial adenomatous polyposis
Hereditary colorectal cancer accounts for about 5-10 per cent of all colorectal cancers 2 . Several hereditary colorectal cancer syndromes, each with different indications for genetic testing based on patient presentation and family history, have been described 2 . Patients at risk of these syndromes, or with documented inheritable colorectal cancers, have increased screening recommendations, and in certain instances are recommended to undergo RRS 2 . One of the more common and well elucidated of these is the FAP syndrome.
FAP is an autosomal dominant syndrome secondary to a germline mutation in the APC gene that accounts for approximately 5 per cent of all heritable forms of colorectal cancer. Individuals affected by the disease develop multiple polyps throughout the entire colon that, if left untreated, would progress to colorectal cancer by age 38-41 years 2 . Extracolonic manifestations of FAP include duodenal adenomas and carcinomas, thyroid cancer, desmoid tumours and osteomas. Consequently, RRS has become the mainstay treatment, typically once the patient has reached 10-19 years of age.
Management strategies for familial adenomatous polyposis
Options for RRS in patients with FAP include total abdominal colectomy with an ileorectal anastomosis (IRA), total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or total abdominal colectomy with end ileostomy. These procedures can be performed either open or laparoscopically. The first two options, when successful, allow the patient to live without a stoma; however, the IRA procedure carries a 4-10 per cent risk of cancer in the rectal remnant 44 . This risk increases with age, and the cumulative risk of rectal cancer 20 years after a colectomy with IRA is about 12 per cent 45 , but can be as high as 27 per cent by age 60 years 46 . Additionally, up to 42 per cent of patients who undergo a colectomy with IRA may need subsequent rectal excision, for either cancer or uncontrollable polyps 45 . Surgery for FAP, regardless of the procedure chosen, is a necessary but major operation, with the possibility of significant complications and morbidity. Common complications include postoperative ileus, anastomotic leakage, anastomotic stricture, surgical-site infections and fistulas 47, 48 . Furthermore, long-term complications include pouch failure, functional outcomes, sexual dysfunction, stomal complications and infertility 49 . A large study from Finland 47 found no difference in complication rates between IPAA (30 per cent) and IRA (21 per cent), but did find a significant difference in conversion to a conventional stoma (3⋅4 per cent for IPAA versus 15 per cent for IRA).
Quality of life after risk-reducing surgery for familial adenomatous polyposis
RRS for FAP can be associated with short-term morbidity and long-term negative HRQOL outcomes. Patients undergoing these RRS are usually young, healthy and asymptomatic. The procedure involves lifelong changes to the patient's gastrointestinal system. Postoperative changes following surgery include difficulties with bowel function and continence such as leakage, discerning gas from faeces, skin problems, dietary restrictions and increased stool frequency 50 . Many studies of these patients using generic HRQOL tools find outcomes comparable to those in the general population once patients had convalesced from the operation 51 -56 . However, a growing body of literature indicates that, using more disease-specific scales, these patients fare worse than the general population 50,53 -55 . An interview-based study from Sweden 57 noted that patients who had RRS for FAP were concerned about gastrointestinal symptoms, insecure about what to eat, embarrassed when visiting toilets outside the home, and worried about follow-up screening procedures.
The changes in bowel function that may affect HRQOL negatively are often too specific to be noted in generic HRQOL tools; however, gastrointestinal dysfunction can become more evident when comparing surgical options. A meta-analysis 50 from 2006 evaluated patients with FAP undergoing IRA versus IPAA. The review included 1 002 patients from studies published between 1991 and 2003 and evaluated both functional outcomes and HRQOL. The IPAA procedure was associated with increased bowel frequency, increased night defaecation, increased use of incontinence pads and a greater likelihood of reoperation within 30 days of the initial procedure. In the review, two studies reported increased social restrictions with IPAA; otherwise no differences were noted in the included HRQOL metrics 50 .
Using a generic HRQOL tool and a FAP-specific survey tool, Andrews and co-workers 51 evaluated patients in Australia at risk of FAP at the time of diagnosis, surgery and follow-up. Overall, 72⋅7 per cent of patients who underwent IRA and 100 per cent of those who had an IPAA reported frequent bowel movements. Patients in the IPAA group had more adverse physical functioning, body image, sexual impact and negative affect than those who did not undergo surgery. Nonetheless, on generic HRQOL measures, the scores were comparable to those in the general population. Van Duijvendijk et al. 58 also used a generic questionnaire (Short Form 36 (SF-36 ® ); QualityMetric, Lincoln, Rhode Island, USA) and a disease-specific questionnaire (European Organisation for Research and Treatment of Cancer colorectal quality-of-life questionnaire (EORTC QLQ-CR38)) to evaluate 279 patients. The generic and disease-specific HRQOL outcomes were not significantly different between the two procedures; however, the SF-36 ® scores for both procedures were significantly lower than those in the general population 58 .
Patients with FAP must consider long-term outcomes because IPAA pouch function may deteriorate over time, particularly more than a decade after initial surgery 59 . Ganschow et al. 53 evaluated long-term HRQOL in patients who had an IPAA with a median follow-up of more than 13 years. They found no significant differences in general HRQOL outcomes compared with those in the general population, although the Gastrointestinal Quality of Life Index was significantly reduced. Furthermore, increased daily bowel movements were significantly associated with decreased quality of life 53 . Interestingly, the presence of extracolonic manifestations of FAP (desmoid tumours or duodenal adenomas) had no significant influence on HRQOL.
Summary
RRS for FAP is a major surgical procedure with inherent early co-morbidities as well as lifelong changes. Although the overall HRQOL of these patients does not appear to deviate significantly from that of the general population, there are definite life and psychosocial alterations that occur with the marked changes to the gastrointestinal tract. Without surgery these patients have a nearly 100 per cent chance of developing a malignancy, but the decision on surgery timing and type of RRS must be individualized for each patient to maximize patient benefit.
Hereditary diffuse gastric cancer
The majority of gastric cancers are sporadic; only 1-3 per cent are associated with hereditary diffuse gastric cancer (HDGC) 60, 61 . Although the mean age of onset in sporadic gastric cancer is 68 years 62 , that in patients with HDGC is much younger: 38 (range 14-85) years 60 . HDGC is attributable to a germline mutation in the CDH1 gene, which encodes for E-cadherin, an epithelial cell-adhesion molecule. More than 155 mutations have been identified 63 . Most lead to a non-functional protein product, resulting in loss of cellular growth control, altered tissue architecture and increased invasiveness into surrounding tissues 64 -66 . HDGC predisposes patients to diffuse gastric cancer (DGC) and invasive lobular carcinoma (ILC) of the breast.
A diagnosis of HDGC in a patient and their family is significant because of the high disease penetrance. The cumulative incidence of DGC by age 80 years is 70 per cent in men and 56 per cent in women 63 . The prognosis for DGC is poor; the 5-year overall survival rate for metastatic gastric cancer is only 5 per cent 62 . Even in patients with localized disease, the 5-year overall survival rate is only about 67 per cent 62 . Early identification of patients with a deleterious CDH1 mutation combined with RRS can be life-saving. The International Gastric Cancer Linkage Consortium (IGCLC) recommends genetic counselling and testing for deleterious CDH1 mutations in families with: two cases of gastric cancer, at least one a DGC; DGC diagnosed before age 40 years; or a personal or family history of DGC and ILC, with at least one before age 50 years 67 .
Management strategies for hereditary diffuse gastric cancer
For patients with HDGC, the first-choice RRS is a prophylactic total gastrectomy (PTG), as this eliminates the patient's subsequent risk of gastric cancer, provided no occult gastric cancer is identified at pathological examination. Both the IGCLC and the NCCN recommend that PTG be discussed with adults with HDGC. The IGCLC 67 recommends PTG after age 20 years, whereas the NCCN 68 recommends PTG between the ages of 18 and 40 years. Additionally, the age of onset of gastric cancer in the proband should be taken into account when counselling patients on the timing of surgery. Some 69 advocate for PTG 5 years earlier than the age at which the youngest family member was diagnosed with DGC, and the NCCN 68 additionally considers PTG for children if a family member was diagnosed with DGC before age 25 years.
PTG involves surgical resection of the entire stomach, from just above the gastro-oesophageal junction to beyond the pylorus, and can be performed either laparoscopically or open. Reconstruction is typically accomplished with a Roux-en-Y oesophagojejunostomy. Intraoperative frozen-section analysis is recommended 68 to confirm that the proximal margin of resection contains normal oesophageal mucosa, and the distal margin contains normal duodenal mucosa. An extended D2 lymphadenectomy is not recommended in PTG.
Postoperative complications for a total gastrectomy performed for known gastric cancers are well described, with a 29 per cent risk of 30-day morbidity and a 5 per cent risk of 30-day mortality 70 . The complication risks of a PTG are likely less than those of a therapeutic total gastrectomy. Single-institution series 71, 72 have reported a 5-9 per cent anastomotic leak rate, 2-13 per cent thromboembolism complication rate and a 15 per cent pulmonary complication rate. Furthermore, any patient who has had a total gastrectomy will require long-term nutritional follow-up, as the absorption of certain nutrients, such as vitamin B 12 , iron and calcium, is drastically altered. Other long-term complications include motility dysfunction such as dumping syndrome.
A significant proportion (69-100 per cent) of patients who have undergone PTG were found to harbour DGC when the entire stomach specimen was submitted for histological examination 69,71 -75 . All of the DGC cases in these single-institution series were staged as T1 N0 M0 (stage IA) 69,71 -75 ; most had multiple microscopic foci that were not identifiable by gross examination of the stomach. Baseline endoscopy is recommended 67,68 before PTG to identify any gastric cancers that have already developed at the time of HDGC diagnosis. However, given that the foci found on histological analysis are generally not seen on gross examination, endoscopic detection of these small multiple foci of DGC is exceedingly difficult.
Surveillance endoscopy
Surveillance endoscopy is recommended in patients who decline PTG at the time of HDGC diagnosis, or in those with HDGC who have a contraindication to PTG owing to medical or psychological co-morbidity. The optimal surveillance frequency is not known; the IGCLC 67 recommends annual endoscopy, whereas the NCCN 68 recommends endoscopy every 6-12 months. Additionally, screening endoscopy is recommended for patients who fulfil clinical criteria for HDGC but have not undergone genetic testing, or have no known deleterious CDH1 mutation despite testing, or have a mutational variant of undetermined significance. Surveillance endoscopy is probably suboptimal in patients with known HDGC and is recommended only for those who cannot, or have not yet, undergone PTG.
Quality of life after prophylactic total gastrectomy
Multiple HRQOL studies have been conducted in patients with HDGC undergoing PTG using standardized validated questionnaires as well as open-ended face-to-face interviews. Of those surveyed, weight loss is one of the biggest concerns 75 . Across multiple studies, weight loss of approximately 15-18 per cent of preoperative weight was demonstrated after PTG 72, 76 . Patients' bodyweight tended to stabilize 6-12 months after surgery 72, 75 . The HRQOL physical functioning scores decreased at 1 month after surgery, but recovery back to preoperative levels was seen by 12 months 75, 76 . However, Muir and colleagues 75 reported that patients had a subsequent decline in HRQOL outcomes at 24 months. Fatigue is another commonly reported symptom after PTG 76 ,with a small group reporting it as a chronic issue 77 .
Gastrointestinal symptoms persistent at 24 months after operation include eating restrictions (88 per cent), discomfort with eating (88 per cent), reflux (63 per cent) and dysphagia (63 per cent) 75 . Worster and co-workers 76 found that, despite recovery of physical functioning scores, eating restrictions did not recover. Alteration in eating habits has been observed in many HRQOL studies 72,75 -77 . These alterations include: describing eating as a necessity and no longer for pleasure (with resulting social repercussions) 77 ; not being able to eat as much per meal 72, 75 ; not being able to tolerate certain foods 72 ; and symptoms with eating, such as sweating/weakness, discomfort, flushing and diarrhoea 72, 75, 76 . For a minority, these symptoms were significant enough to affect patients' ability to work and to have a full social life 77 .
Worster et al. 76 identified a strong correlation between mental and physical functioning, and found that the drop in mental functioning scores at 1 month after surgery recovered within 3-9 months. They also found no difference in mental functioning scores (vitality, social functioning, mental health, impact of emotional states on daily activities) between patients who underwent PTG and those who had surveillance endoscopy 76 . Finally, they found no difference between preoperative and postoperative emotional functioning scores. In an open-ended interview, Hallowell and colleagues 77 found there was relief of anxiety across all patients who had undergone PTG. These authors believed that no longer worrying about gastric cancer was a major benefit to undergoing PTG. However, a few patients also reported PTG as a threat to their identity, feeling like they were a 'different person following surgery' 77 .
Many patients with HDGC who underwent PTG reported a negative impact on their finances, at least in the short to medium term 77 . One study 72 reported that all patients who were working before surgery eventually returned to work afterwards. In contrast, another study 77 noted that a few patients could not work full-time owing to chronic gastrointestinal symptoms and fatigue.
Summary
For adult patients diagnosed with HDGC, PTG is the current standard-of-care recommendation, based on high penetrance of the CDH1 mutation and the high mortality associated with gastric cancer once it becomes detectable. Although PTG is a complex surgery with inherent morbidity and changes in quality of life, most patients are able to tolerate this life-altering procedure with some preservation of HRQOL and significant reductions in anxiety relating to a potential cancer diagnosis. Surveillance endoscopy is offered to patients who cannot or decline to undergo PTG; however, it is unreliable in its ability to detect early DGC at a stage where impact on overall survival is minimal.
Conclusion
Patients with hereditary cancer syndromes are faced with multiple complex, life-altering decisions on how to manage their increased cancer risk. In contrast to patients who have already been diagnosed with cancer, unaffected mutation carriers generally have time to gain information and explore different strategies. Depending on the syndrome, multidisciplinary discussions with genetic counsellors, surgeons, primary care physicians, oncologists, gastroenterologists, endocrinologists, dietitians and physiotherapists are necessary to provide effective and timely counselling. For some hereditary cancer syndromes, RRS increases life expectancy, decreases cancer anxiety, and is associated with improvements in HRQOL measurements. However, RRS is irreversible and can be associated with marked early and late complications. With increasingly identifiable and testable mutations, RRS will likely become more widespread. Patients considering RRS should be fully apprised of the short-and long-term ramifications of their decisions.
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